Statin/Vitamin D & Migraine Study
The investigators are studying if taking simvastatin and vitamin D together will help prevent episodic migraines. Simvastatin is an FDA approved drug that is typically used to treat high cholesterol and reduce the risk of stroke and heart attack. Vitamin D is a vitamin found in certain foods like some types of fish, and in nutritional supplements. This study is 9 months long. Some people who participate will receive simvastatin and vitamin D, and some people will receive a placebo. A placebo is a "sugar pill" that looks like medication but does not have any active ingredients in it.
The investigators hypothesize that taking vitamin D and simvastatin daily may reduce the number of migraines people who have episodic migraine get.
Dietary Supplement: Vitamin D
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Combined Statin and Vitamin D Therapy for Prophylactic Treatment of Episodic Migraine|
- Migraine Frequency: Change From Baseline 12-week Period to Weeks 1 to 12 [ Time Frame: Weeks 1 to 12 ] [ Designated as safety issue: No ]
- Migraine Frequency: Change From Baseline 12-week Period to Weeks 13 to 24 [ Time Frame: Weeks 13 to 24 ] [ Designated as safety issue: No ]
|Study Start Date:||September 2010|
|Study Completion Date:||January 2015|
|Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Experimental: Simvastatin and vitamin D
Participants in this arm will receive simvastatin + vitamin D.
simvastatin, 20 mg, twice daily for 6 monthsDietary Supplement: Vitamin D
Vitamin D3, 1000 IU, twice daily for 6 months
Placebo Comparator: Placebo "Sugar Pill"
Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a "sugar pill".
Two placebo pills, taken twice daily for 6 months
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225263
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Catherine Buettner, MD, MPH||Beth Israel Deaconess Medical Center|
|Study Director:||Rami Burstein, PhD||Beth Israel Deaconess Medical Center|